1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Fielmann AG

Fielmann AG

FLMNF
Fielmann AGUS flagOther OTC
50.75
USD
- -
- -
4.26BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.78
14.6
15.48
15.92
16.5
17
18.11
17.01
19.98
20.94
23.46
26.99
29.01
29.29
Basic EPS, GAAP
1.64
1.87
1.97
1.98
2
2.01
2.05
1.39
1.63
1.23
1.49
1.81
2.43
2.48
Free Cash Flow per Basic Share
-0.28
1.4
1.29
2.03
2.63
1.39
2.4
2.24
3.1
1.9
2.33
3.9
4.53
- -
Dividend per Share
1.4
1.51
1.66
1.81
1.86
1.91
1.96
- -
1.2
1.5
0.75
1
1.15
- -
Book Value per Share
2.1
2.6
2.75
2.8
6.97
7.12
1
1
1
8.07
7.89
9.23
10.62
- -
Tangible Book Value per Share
6.42
6.84
7.27
7.41
7.43
7.47
7.24
5.57
6.34
5.57
3.95
2.23
3.83
- -
Basic Weighted Avg Shares
84
84
84
84
84
84
84
84
84
84
84
84
84
84
Sales/Revenue/Turnover
1,157
1,226
1,300
1,337
1,386
1,428
1,521
1,429
1,678
1,759
1,971
2,267
2,435
2,456
Operating Margin (%)
17.19
18.47
18.49
17.95
18.35
17.5
16.71
23.72
13.06
13.38
14.69
15.09
17.14
17.37
Depreciation Expense
35
38
39
40
42
45
129
158
177
180
196
215
230
124
Net Income, GAAP
138
157
166
166
168
169
172
116
137
104
125
152
204
207
Effective Tax Rate (%)
28.68
27.96
28.96
29.1
30.48
30.8
30.15
31.16
31.07
31.57
32.61
29.55
29.55
29.16
Profit Margin (%)
11.93
12.83
12.73
12.44
12.09
11.83
11.32
8.15
8.16
5.89
6.33
6.72
8.37
8.45
Working Capital
311
326
332
317
330
309
235
162
172
98
-116
-289
109
- -
LT Debt
1
1
1
1
2
1
297
343
368
385
421
467
782
- -
Total Equity
594
630
668
686
695
709
727
836
873
853
851
923
998
- -
Return on Invested Capital (%)
23.57
25.88
25.65
24.46
24.97
24.2
19.44
19.6
11.51
11.83
13.79
14.76
15.86
- -
Return on Capital (%)
77.82
76.99
71.4
69.34
39.68
27.76
31.96
22.29
23.43
11.27
10.83
10.99
12.55
25.19
Return on Common Equity (%)
80.15
79.7
73.67
71.35
40.85
28.53
50.47
138.58
162.92
27.2
18.61
21.2
24.45
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
98
- -
LT Borrowings
- -
279
- -
LT Finance Leases
- -
503
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
84
- -
Market Capitalization
4,294
4,289
3,834

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
676
- -
Cash, Cash Equivalents & STI
- -
235
- -
Accounts Receivable, Net
- -
46
- -
Inventories
- -
222
- -
Total Current Liabilities
- -
567
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
98
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.21%
3.69%
8.15%
Free Cash Flow
21.12%
21.08%
16.12%
Net Income, GAAP
4.11%
13.9%
33.65%
Sales/Revenue/Turnover
6.67%
11.35%
7.43%
Total Cash Common Dividend
- -
-3.09%
14.96%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
528
552
604
578
2,267
2025
605
623
620
599
2,435
2026
613
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.49
0.52
0.48
- -
1.81
2025
0.65
0.62
0.62
- -
2.43
2026
0.66
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1.15
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Marc Fielmann
Full Time Employees
20,221
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
Fuhlsbuettler Strasse 399 Hamburg HA Germany 22083
IPO Date
Sep 30, 2013
Website
fielmann-group.com
Similar Companies
Shandong Weigao Group Medical Polymer Company Limited (1066.HK)
Fisher & Paykel Healthcare Corporation Limited (FPH.AX)
United Health Products, Inc. (UEEC)
Kawamoto Corporation (3604.T)
Ansell Limited (ANN.AX)
Teleflex Incorporated (TFX)
Business
Fielmann Group AG Fielmann Group AG operates as a leading provider of vision care and audiology products and services through an omnichannel model encompassing digital channels and over 1,200 retail stores worldwide. The company manufactures and sells prescription glasses, eyewear frames and lenses, sunglasses, contact lenses, accessories, hearing aid systems and related accessories, and personal protective equipment under brands including fielmann, Optika Clarus, Optica & Audiologia Universitaria, Medical Optica Audicion, and SVS Vision; it also delivers primary eyecare services such as free vision and hearing tests, optician consultations, and eye health checkups. Fielmann Group AG serves approximately 29 million active customers, targeting individual consumers and corporate clients including employers seeking screen workplace glasses, safety eyewear, magnifier glasses, and smart glasses solutions, with operations spanning Germany, Switzerland, Austria, Spain, North America, and other international markets. Founded in 1972 by Günther Fielmann, with headquarters in Hamburg, Germany, the company maintains full value chain integration from design and manufacturing to retail distribution and professional services; it functions as a subsidiary of Korva SE and employs around 24,000 people. In July 2023, Fielmann Aktiengesellschaft rebranded to Fielmann Group AG to reflect its expanded scope. Recent developments include the July 2024 acquisition of Shopko Optical in the United States to bolster North American expansion; a strategic partnership with Ubimax announced in late 2024 to integrate remote support software with smart glasses for corporate digitalization; and in 2025, ZEISS Vision Care's investment in Ocumeda, a tele-ophthalmology platform previously backed by Fielmann, at a €100 million valuation to scale connections between patients, optical stores, and ophthalmologists. On September 1, 2025, the group relocated its head office to Fuhlsbüttler Strasse in Hamburg's Barmbek-Nord district after nearly 40 years at Weidestrasse; it also achieved uplisting to the MDAX index in September 2025 and reported strong first-half 2025 sales growth of 12 percent alongside profitability targets.

Company News

APIChatGPT

  • seekingalpha.com

    Fielmann Group AG (FLMNY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Fielmann: Margin Recovery Likely, But Still Not Priced In